1.80
-0.04 (-2.17%)
| 前收盘价格 | 1.84 |
| 收盘价格 | 1.84 |
| 成交量 | 560,682 |
| 平均成交量 (3个月) | 858,767 |
| 市值 | 231,614,176 |
| 价格/销量 (P/S) | 0.500 |
| 股市价格/股市净资产 (P/B) | 1.51 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业毛利率 | -3.46% |
| 营业利益率 (TTM) | -23.28% |
| 稀释每股收益 (EPS TTM) | -0.160 |
| 季度收入增长率 (YOY) | -21.20% |
| 季度盈利增长率 (YOY) | 289.40% |
| 总债务/股东权益 (D/E MRQ) | 11.58% |
| 流动比率 (MRQ) | 4.12 |
| 营业现金流 (OCF TTM) | 4.43 M |
| 杠杆自由现金流 (LFCF TTM) | -4.36 M |
| 资产报酬率 (ROA TTM) | 0.70% |
| 股东权益报酬率 (ROE TTM) | -4.92% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Organogenesis Holdings Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.86 |
|
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 46.49% |
| 机构持股比例 | 54.09% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合